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Evidence-Based Medicine
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Background: Non-small cell lung cancer (NSCLC) patients with N1 disease have variable outcomes, and
additional prognostic factors are needed. The number of positive lymph nodes (LNs) has been proposed as a
prognostic indicator. However, the number of positive LNs depends on the number of LNs examined from
the resection specimen. The lymph node ratio (LNR) can circumvent this limitation. The purpose of this
study is to evaluate LNR as a predictor of survival and recurrence in patients with pathologic N1 NSCLC.
Methods: We systematically reviewed studies published before March 17, 2016, on the prognostic value of
LNR in patients with pathologic N1 NSCLC. The hazard ratios (HRs) and their 95% confidence intervals
(CIs) were used to combine the data. We also evaluated heterogeneity and publication bias.
Results: Five studies published between 2010 and 2014 were eligible for this systematic review with metaanalysis. The total number of patients included was 6,130 ranging from 75 to 4,004 patients per study. The
combined HR for all eligible studies evaluating the overall survival (OS) and disease-free survival (DFS) of
N1 LNR in patients with pathologic N1 NSCLC was 1.53 (95% CI: 1.22–1.85) and 1.64 (95% CI: 1.19–2.09),
respectively. We found no heterogeneity and publication bias between the reports.
Conclusions: LNR is a worthy predictor of survival and cancer recurrence in patients with pathological
N1 NSCLC.
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Introduction
Lung cancer causes about 1.4 million deaths per year worldwide (1). Non-small cell lung cancer (NSCLC) accounts
for approximately 85% of lung cancer. Only a fraction of
NSCLC patients are diagnosed with localized, early-stage
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disease, when curative-intent surgical resection is possible
(2,3). After surgery, the status of regional lymph node (LN)
involvement is the most important prognostic factor (4).
Pathologic nodal involvement (pN1-3) connotes a poor
prognosis, but also predicts the likelihood of benefit from
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Literature search
Databases: PubMed, ISI Web of science
Manually search: refernce section of selected
studies and relevant reviews

423 citations retrieved
402 citations excluded after screening
21 articles assessed for eligibility
1 citations coming from same population
2 articles without related data
13 articles about N2 or N1 plus N2
5 articles finally included

Figure 1 Flow chart representing the process of literature search and study selection.

postoperative adjuvant therapy. Multiple investigators have
demonstrated the heterogeneity in survival of patients with
pN0 resections, suggesting the possibility that a significant
proportion of these patients are understated, probably
because LN metastasis is missed (5-8). However, the
survival of patients with pathologic N1 is also heterogenous,
ranging from a 5-year survival of 54% to 34% in the
International Association for the Study of Lung Cancer
(IASLC) Lung Cancer Staging Project database (4). The
reported risk of recurrence for patients with pathologic
Stage IIA-IIB disease ranges from 7% to 55% (9).
These results suggest a need to identify patterns of
LN involvement that more accurately predict survival,
particularly of patients with N1 disease (10,11). Because
the thoroughness of nodal examination interacts with
the likelihood of detecting nodal metastasis, the number
of positive LNs may depend on by the number of LNs
examined from the resection specimen. Therefore, the
prognostic accuracy of the actual number of positive LNs is
potentially restricted (12). The lymph node ratio (LNR)—
the number of positive LNs divided by the number of
LNs examined- has been suggested to be a more accurate
prognostic indicator than the number of LNs with
metastasis in different types of cancer including thyroid,
gastric, colorectal, and cancer (13-19).
The prognostic value of the LNR in N1 NSCLC
remains controversial. We conducted a meta-analysis
of published reports in order to evaluate the LNR as
a predictor of survival and recurrence in patients with
pathological N1 NSCLC.
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Methods
Search strategy
We comprehensively search PubMed and ISI Web of
Science using an upper date limit of March 17, 2016, and
no lower date limit. Search terms included: “lymph node
ratio”, “LNR” “non-small cell lung cancer”, “NSCLC”, “N1
node”. References cited in the identified publications were
also used to complete the search.
Inclusion criteria
Two of the authors (Qian Li, Ping Zhan) independently
determined the eligibility of the studies retrieved from
the databases and bibliographies (Figure 1). Studies
eligible for inclusion in this meta-analysis met the
following criteria: include early stage NSCLC patients
who underwent surgical resection; include the patients
harboring pathological N1 disease; provide information
on survival (studies investigating response rates only were
excluded); have a follow-up time not less than two years;
and for multiple publications reporting on the same patient
population, only the most recent, or the most complete,
report was included. Discordance among reviewers was
resolved by mutual agreement after further discussion.
Exclusion criteria
Publications were excluded if they met any of the following
criteria: (I) case series, case reports, reviews and conference
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Table 1 Clinical and methodological characteristics of included studies
First author, year

Country

Stage

N pts

Time (year)

HR (95% CI)
OS

DFS

Wisnivesky, 2011

US

T1a-T3N1

1,682

1992–2005

1.56 (1.10–2.21)

1.55 (1.03–2.33)

Jonnalagadda, 2011

US

N1 positive

4,004

1988–2007

1.51 (1.04–2.19)

1.58 (1.04–2.40)

Taiwan/China

IIA

75

2005–2011

2.81 (1.08–7.31)

2.36 (1.32–4.22)

Li, 2013

Wu, 2014

China

II

206

1999–2009

1.57 (1.01–2.45)

–

Liu, 2013

Taiwan/China

II

163

1992–2010

1.40 (0.85–2.35)

–

CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; N pts, number of patients; OS, overall survival; US, the United States
of America.

reports; (II) duplicate publications; (III) studies based on
overlapping cohorts from the same institution.
Data extraction and quality assessment
The final articles included were assessed independently
by two reviewers (Qian Li and Ping Zhan) using the
“Newcastle-Ottawa Scale for Assessing the Quality of NonRandom Studies in Meta-analyses” (20). Given the variability
in the quality of cohort studies found in our initial literature
search, we considered studies to be of high quality if they
achieved a score of six or more on the Newcastle-Ottawa
Scale. Data retrieved from the reports included first author,
year of publication, country, lung cancer stage, number of
patients, time, and survival data (Table 1).
Definition of outcomes
The primary outcome was overall survival (OS), measured
from the date of surgery to the date of death or date of last
follow-up; the secondary outcome was disease-free survival
(DFS), measured from the date of surgery to the date of
disease progression or date of last follow-up.
Statistical methods
The hazard ratios (HRs) and their 95% confidence
intervals (CIs) were combined to give the pooled effective
value. Heterogeneity of the individual HRs was calculated
with Chi-squared tests according to Peto’s method (21).
Heterogeneity test with I 2 statistic was performed. All
the studies included were categorized by OS and DFS.
Individual meta-analysis was conducted in each subgroup.
If HRs were found to have acceptable homogeneity, a
fixed effect model was used for secondary analysis; if not, a
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random effect model was used.
In this meta-analysis, Der Simonian Laird random
effects analysis was used to estimate the effect of N1 LNR
on survival (22). HR >1 indicates better survival of low N1
LNR, conversely, HR <1 implies worse survival for the
group with high N1 LNR. The impact of N1 LNR on
survival was considered to be statistically significant if the
95% CI did not overlap with 1. Horizontal lines represent
95% CIs. The HR point estimate was reflected in each
box and the box area is proportional to the weight of the
study. The diamond (and broken line) represents the overall
summary estimate, with CI represented by its width. The
unbroken vertical line is set at the null value (HR =1.0).
Existence of publication bias was evaluated by the
methods of Begg et al. (23). Moreover, a contour-enhanced
funnel plot was performed to aid in interpreting the funnel
plot (24). Publication bias can lead to the asymmetry that
studies appear to be missing in areas of low statistical
significance, while it is less likely to cause the funnel
asymmetry under the circumstance of studies missing in
areas of high statistical significance. Intercept significance
was determined by the t-test suggested by Egger (25).
Statistical analysis was conducted using STATA version 11.0
(Stata Corporation, College Station, TX, USA).
Results
Study selection and characteristics
Five studies published between 2010 and 2014 were eligible
for this systematic review with meta-analysis (26-30). All
reported the prognostic value of LNR in patients with
pathologic N1 NSCLC. The total number of patients
included was 6,130, ranging from 75 to 4,004 patients
per study. The major characteristics of the five eligible
publications are reported in Table 1.
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%

Study
ID

ES (95% CI)

Juan P Wisnivesky, 2011

1.56 (1.10, 2.21) 32.20

Sirisha Jonnalagadda, 2011

1.51 (1.04, 2.19) 30.00

Ching-Feng Wu, 2014

2.81 (1.08, 7.31) 1.02

Zi-Ming Li, 2013

1.57 (1.01, 2.45) 19.14

Chao-Yu Liu, 2013

1.40 (0.85, 2.35) 17.64

Overall (I-squared =0.0%, P=0.940)

1.53 (1.22, 1.85) 100.00

0 0.5 1

Weight

2

Figure 2 Meta-analysis of the association between N1 LNR and OS in patients with pathological N1 non-small cell lung cancer (NSCLC).
Results are presented as the individual and summarized hazard ratios (HRs) with 95% confidence interval (CI). Each box represents the
OR point estimate, and its area is proportional to the weight of the study. The diamond (and broken line) represents the overall summary
estimate, with CI represented by its width. The unbroken vertical line is set at the null value (OR =1.0). LNR, lymph node ratio; OS, overall
survival; OR, odds ratios.

Study

%

ID

ES (95% CI)

Juan P Wisnivesky, 2011

1.55 (1.03, 2.33) 47.29

Sirisha Jonnalagadda, 2011

1.58 (1.04, 2.40) 43.21

Ching-Feng Wu, 2014

2.36 (1.32, 4.22) 9.50

Overall (I-squared =0.0%, P=0.591)

1.64 (1.19, 2.09) 100.00

0 0.5 1

Weight

2

Figure 3 Meta-analysis of the association between N1 LNR and DFS in patients with pathological N1 NSCLC. Results are presented as the
individual and summarized HR with 95% CI. Each box represents the OR point estimate, and its area is proportional to the weight of the
study. The diamond (and broken line) represents the overall summary estimate, with CI represented by its width. The unbroken vertical line
is set at the null value (OR =1.0). LNR, lymph node ratio; DFS, disease-free survival; NSCLC, non-small cell lung cancer; CI, confidence
interval; OR, odds ratios.

Meta-analysis
The results of the meta-analysis are reported in Figures
2, 3 and 4. Overall, the pooled HR for all eligible studies
evaluating the OS of high N1 LNR in resected early-stage
NSCLC was 1.53 (95% CI: 1.22–1.85) using the fixed effects
model (Figure 2). The heterogeneity between the reports
was not significant (I2=0.0%, P=0.940). The HR indicates

© Translational lung cancer research. All rights reserved.

that in patients with pathologic N1 NSCLC, those with
higher LNR had poor survival compared to those with lower
LNR. Higher LNR was also associated with shorter DFS,
as the pooled HR for DFS was 1.64 (95% CI: 1.19–2.09)
(only 3 of the 5 studies had data available for DFS) (Figure 3).
Again, the heterogeneity between the reports was not
significant (I2=0.0%, P=0.591).
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Begg’s funnel plot with pseudo 95% confudence limits
1.5

log[HR]

1

0.5

0

−0.5
0

0.2

0.4
s.e. of: log[HR]

0.6

Figure 4 Begg’s funnel plot for detecting publication bias. There is
no publication bias detected (P=0.806).

Begg’s funnel plot was performed to assess publication
bias in the included literature. All five eligible studies
investigating NSCLC patients yielded a Begg’s test score of
P=0.806. Furthermore, according to the contour-enhanced
funnel plot (Figure 4), no evidence of publication bias was
found in all five studies.
Discussion
The status of LNs is a powerful determinant of survival in
NSCLC and an essential component of the tumor, node,
metastasis (TNM) classification for lung cancer (3,4). The
TNM NSCLC staging system currently uses only the
anatomic location of LNs to define N status. The LNR has
been shown to be an important prognostic factor in several
malignancies (13-19) and may overcome the limitation in
the number of LNs sampled. Consistent with this notion
Bria et al. showed an association between the LNR and lung
cancer outcomes (12).
In this meta-analysis, we have combined five published
studies including 6,130 NSCLC patients with pathologic
N1 NSCLC to evaluate the prognostic value of the LNR.
Our results show high N1 LNR is significantly associated
with worse OS [HR 1.53 (95% CI: 1.22–1.85)] and DFS [HR
1.64 (95% CI: 1.19–2.09)]. Therefore, the LNR should be
considered a predictor of survival and recurrence in patients
with pathologic N1 NSCLC. The higher LNR, the worse
the prognosis.
Surgical resection is the key curative treatment modality
for patients with N1 NSCLC (31). However, patients
with pathologic N1 disease have heterogeneous outcomes
(4,9,32). For example, in the IASLC’s Lung Cancer Staging
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Project database, intercontinental pathologic N1 5-year
survival rates ranged from 54% in Asia to 34% in Europe (4).
Some have proposed that this survival heterogeneity
is partly driven by heterogeneity in staging accuracy
caused by heterogeneity in the thoroughness of hilar and
intrapulmonary LN retrieval (33-35). The value of the
LNR may be in partially adjusting for this heterogeneity in
thoroughness of nodal evaluation.
Current guidelines on lung cancer surgery do not
specify the number of LNs that should be sampled for
adequate staging. Several large population-based studies
have suggested that more than ten LNs should be examined
in the resection specimens of patients categorized as
pathologic node-negative (5-8). There has been less
emphasis on the need for thorough N1 nodal examination
in patients with pN1 disease. However, the burden of
metastatic disease, reflected by the number or proportion
of LNs with metastasis, may have great prognostic
significance. The total number of N1 nodes detected with
metastasis is, theoretically, limited by the total number of
LNs examined. Our results support using the LNR as an
independent means of risk-stratifying patients with pN1,
and potentially identifying patients who might benefit from
more intense postoperative adjuvant therapy, might need
closer surveillance, or might be targeted for enrollment into
clinical trials of novel adjuvant therapies.
Potential limitations of our study include the limitation
to articles published in the English language, the possibility
of a publication bias, since we could not include studies that
may not have been published because of negative results,
and the small number of eligible studies in this metaanalysis. Despite these limitations, our study shows that
a high LNR connotes a poor prognosis in patients with
resected N1 NSCLC. The LNR should be considered in
determining post-operative management of patients with
pN1, because it provides a more accurate assessment of
prognosis.
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